Patient characteristics (N = 40)
| . | Total . | Valganciclovir . | Valaciclovir . |
|---|---|---|---|
| Age, y, median (range) | 59 (25–83) | 59 (28–76) | 56 (25–83) |
| No. of prior treatments, median (range) | 2 (0–10) | 2 (0–10) | 2 (0–10) |
| Diagnosis | |||
| ALL | 1 | 1 | 0 |
| CLL | 27 | 15 | 12 |
| Richters | 2 | 1 | 1 |
| MZL | 1 | 0 | 1 |
| HCL | 1 | 0 | 1 |
| T-cell large granulocytic lymphocytic leukemia | 2 | 1 | 1 |
| T-cell lymphoma | 3 | 1 | 2 |
| T-PLL | 3 | 1 | 2 |
| Regimen | |||
| CFAR | 23 | 14 | 9 |
| Alemtuzumab plus rituximab | 2 | 0 | 2 |
| Alemtuzumab single agent | 5 | 1 | 4 |
| Alemtuzumab plus pentostatin | 6 | 3 | 3 |
| Alemtuzumab plus hyper CVAD | 3 | 1 | 2 |
| Alemtuzumab plus methotrexate/asparaginase | 1 | 1 | 0 |
| . | Total . | Valganciclovir . | Valaciclovir . |
|---|---|---|---|
| Age, y, median (range) | 59 (25–83) | 59 (28–76) | 56 (25–83) |
| No. of prior treatments, median (range) | 2 (0–10) | 2 (0–10) | 2 (0–10) |
| Diagnosis | |||
| ALL | 1 | 1 | 0 |
| CLL | 27 | 15 | 12 |
| Richters | 2 | 1 | 1 |
| MZL | 1 | 0 | 1 |
| HCL | 1 | 0 | 1 |
| T-cell large granulocytic lymphocytic leukemia | 2 | 1 | 1 |
| T-cell lymphoma | 3 | 1 | 2 |
| T-PLL | 3 | 1 | 2 |
| Regimen | |||
| CFAR | 23 | 14 | 9 |
| Alemtuzumab plus rituximab | 2 | 0 | 2 |
| Alemtuzumab single agent | 5 | 1 | 4 |
| Alemtuzumab plus pentostatin | 6 | 3 | 3 |
| Alemtuzumab plus hyper CVAD | 3 | 1 | 2 |
| Alemtuzumab plus methotrexate/asparaginase | 1 | 1 | 0 |
ALL indicates acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; MZL, marginal zone lymphoma; HCL, hairy cell leukemia; T-PLL, T-cell prolymphocytic leukemia; CFAR, cyclophosphamide, fludarabine, alemtuzumab, rituximab; and CVAD, cyclophosphamide, vincristine, adriamycin, dexamethasone.